A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment

作者：Kuo Yung Chih^*; Rajesh Rajendiran

来源：Journal of the Taiwan Institute of Chemical Engineers, 2017, 77: 92-105.

DOI：10.1016/j.jtice.2017.05.011

• Amyloid beta
• Tau protein
• Familial factor
• Targeting
• Metabolic dysfunction
• Bionanomaterials

Several million people in the world are affected by dementia, especially by Alzheimer's disease (AD), a frequently encountering neurodegenerative disorder in the brain, and it is predicted to double by every 20 years. The growing population of aging leads to an increase in the number of individuals at the risk of AD. Up to now, the epidemiological other than age and familial factors of AD remain elusive, although amyloid beta peptide (extracellular neuritic plaque) and tau protein (intracellular neurofibrillary tangle) are regarded as the two major pathological features. In addition, a few critical issues emerge at the moment and are required to be ascertained. Is there any scheme for resolving the exact mechanism of AD? Are there any vaccines and drugs to completely reverse the AD progress? Is there any possibility for the early stage detection of AD? And, is there a permanent cure for AD? These questions are haunting researchers to identify the best pharmaceuticals and accurate pathways for AD-related evolution. This paper discusses about the etymology, pathology, therapeutic strategy and technology on recent advancement, facilitating scientists and medical practitioners to discover the physiological causes and therapeutic targets to improve AD treatment.

• 出版日期2017-8